Starling Oncology, Inc.: cash_and_restricted_cash
| Value | {"amount": 49669000, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"} |
|---|---|
| Period | (as of 2024-12-31) |
| Status | current |
| Entity | Starling Oncology, Inc. |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/1000ab92-aa5c-4747-ba47-5ae86262eb5f
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001799191-25-000014Retrieved: 2026-08-19T18:08:38.724184+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001799191/cash-and-restricted-cash/2024-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/1000ab92-aa5c-4747-ba47-5ae86262eb5f
History
- no predecessors — first report